It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...
The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...
Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk-stratified groups according to the new Cutaneous Lymphoma International ...
Pharmaceutical Technology on MSN
March Bio’s MB‑105 gains FDA RMAT for CD5+ T‑cell lymphoma
Preliminary outcomes from the safety run-in cohort will be presented at the American Society of Hematology 2025 Annual ...
Pharmaceutical Technology on MSN
FDA approves AbbVie’s Epkinly to treat follicular lymphoma
The US Food and Drug Administration (FDA) has approved AbbVie’s Epkinly (epcoritamab-bysp) to treat adult patients with ...
While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...
Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...
As PET scans fall short, blood-based circulating tumor DNA testing shows promise in monitoring large B-cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback